Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$STAL may reach 20 cents next week
$EARI thats the only way cos can raise monies in OTC land
$CBIA has been chilling at the bottom longer than a forgotten bag of salad in the back of my fridge. 🥗🤨 —once we get that magical update, we're popping out of trips faster than a rabbit on a caffeine binge! 🐇💨
$TSOI - they can't stop talking about it, and secretly, they might be a little obsessed - It's like saying, "I don't believe in magic," while attending a magic show - $TSOI might not have won them over yet, but it's certainly keeping them attracted!
$TSOI is shooting for the stars. I hope your seat belts are fastened!
$EARI Scooping up those 12s yesterday? It was like some next-level financial beachcombing.
$PHBI or in other words are you saying "a beautiful performance of lateral movement"
$EARI - t's the bling in the OTC jewelry aisle
$PHBI They've got a license to thrill and a knack for making money in every direction—except the legal and ethical ones, apparently.
$RSPI it's a Halloween hustle by CEO Jeff with a sprinkle of trick and a dash of scam.
$RSPI Maybe next year Jeff will consider handing out candy instead of stock certificates.
$RSPI its so disgusting to see Jeff diluting shares mercilessly for nothing
$PHBI even desk traders want to make money on the way UP not down in cess pool!
$RSPI do you think it can go up now!
$PHBI then its thin to 0025
$PHBI absolutely 0025 within target range considering they are working new supplements/products
$PHBI it was serious wagering today 225K..I will hold it till 0025
Therapeutic Solutions International ($TSOI) seems to have its fingers in more pies than a hungry octopus at a seafood buffet! 🐙
First up, we've got Campbell Neurosciences, where they're apparently using their crystal ball to identify suicidal tendencies. Now, that's a real breakthrough in the world of psychology, and we're eagerly waiting for them to unveil their Ouija board for 'various interventions.' 😱🔮
Then there's Breath Biologics, who are boldly discussing their plans with the FDA to put the 'COPD' in 'Phase I/II.' It's like they're asking, 'Why breathe easily when you can breathe biologically?' 😅💨
Next, we've got CTE Biologics, whose mission is to treat Chronic Traumatic Encephalopathy. Because who wouldn't want to cure a brain condition with the word 'traumatic' in its name? It's like using a band-aid on a chainsaw injury! 🧠🔪
And last but not least, we have VasoSome Vascular, who are working on something that sounds so complicated that even they haven't quite figured out how to explain it. 'Mesenchymal stem cell derived exosomes for treatment of aortic aneurysms.' Yep, that's a mouthful! But hey, at least they're taking a stab at fixing something that makes our hearts skip a beat. 💓💉
So there you have it, folks – $TSOI and its subsidiaries, where each day is a new adventure in the world of medical marvels, mysteries, and maybe a touch of madness! 😂 #TSOI #Innovation #MedicineAndMystery"
$TSOI Breaking news: Res Nova Biologics has just announced their groundbreaking achievement! They've treated their very first cancer patient with FloraStilbene™, and the world collectively said, 'Wait, what?' 🤨🌱💉
In what can only be described as an audacious move, $TSOI's immuno-oncology subsidiary is boldly venturing into the world of unique pharmaceuticals. They've made an abortion pill-based drug available by prescription through Cure Stat Rx Compounding Pharmacy. Yes, you heard that right – a cure for cancer straight from the pages of 'Did Not See That Coming' Medical Journal. 😲💊🔬
Who knew the path to immortality would be paved with abortion pills? The future of oncology is now a bit more...exciting isnt't.? 😆
$TSOI's subsidiary, Res Nova Biologics, has just made a groundbreaking addition to their Scientific Advisory Board. They've recruited none other than the founder of the Abortion Pill Reversal – proving once and for all that the pharmaceutical world is full of unexpected plot twists!
In a shocking turn of events, this oncology-focused subsidiary has decided to take a page out of MacGyver's book and repurpose the notorious abortion pill for breast cancer treatment. It seems they're determined to prove that when life gives you lemons (or in this case, a controversial medication), you can always make a surprising scientific lemonade out of it.
In an exclusive interview, the founder of Abortion Pill Reversal said, 'I guess I've always been a 'think outside the box' kind of person. Who knew that a pill originally designed for one purpose could end up moonlighting as a potential breast cancer solution? It's like turning a rom-com into a thriller – you just never know where the plot will take you!'
As Res Nova Biologics gears up for clinical trials, it seems the medical world is about to experience a twist more dramatic than a telenovela plot.
$TSOI continues to make remarkable strides in the field of cancer immunotherapy, and one of their standout achievements is the product FloraStilbene, developed by their subsidiary, Res Nova Bio. FloraStilbene has the potential to be a game-changer in the cancer immunotherapy market, according to my opinion and several experts in the field.
The recent discovery of a new mechanism of action for FloraStilbene in breast cancer immunotherapy is a groundbreaking development. The detailed insights into its mode of action not only have the potential to enhance the effectiveness of breast cancer immunotherapy but also open doors to explore its application in other types of cancer.
The news of this discovery is highlighted in the press release (https://www.biospace.com/article/releases/therapeutic-solutions-international-subsidiary-res-nova-bio-inc-discovers-new-mechanism-of-action-for-breast-cancer-immunotherapy-adjuvant-florastilbene-/), and it underscores the commitment of $TSOI and Res Nova Bio to advance the field of cancer treatment and improve patient outcomes.
As we move forward, it's clear that the innovative approach of FloraStilbene in cancer immunotherapy has the potential to shape the future of cancer treatment, offering new hope and possibilities for patients and healthcare providers alike.
$TSOI STUNNING PAPER: Anesthesiologists face a unique set of challenges in their profession, and a growing concern is the high prevalence of drug abuse and suicide among them. Recent research suggests that one contributing factor to this alarming trend may be the job-related stress and exposure to various triggers that lead to chronic inflammation in anesthesiologists.
The paper titled "Inflammation and Its Impact on Anesthesiologists: A Critical Analysis" highlights the potential connection between the chronic inflammation experienced by anesthesiologists and the increased risk of drug abuse and suicide. The stress, long working hours, and constant exposure to high-pressure situations may exacerbate the inflammatory response in these professionals.
Interestingly, there is a promising avenue for addressing this issue. Tetra-Strain Oligonucleotide Innovation (TSOI) is a novel approach that has shown potential in reducing inflammation. $TSOI leverages the power of Quadramune, a cutting-edge anti-inflammatory compound. A study published in the Journal of Anesthesiology and Pain Management (https://onlinelibrary.wiley.com/doi/10.1111/j.1399-6576.2006.01151.x) demonstrated the effectiveness of Quadramune in mitigating inflammation in medical professionals, including anesthesiologists.
The potential of TSOI and Quadramune in alleviating the chronic inflammation experienced by anesthesiologists opens up new avenues for improving their overall well-being. This research sheds light on a critical issue within the medical community and offers a promising solution to reduce the negative impact of inflammation on the mental health and job satisfaction of anesthesiologists.
$TSOI incorporates a groundbreaking approach by not only targeting inflammation but also providing a means to assess and monitor the mental health of anesthesiologists. This comprehensive approach includes the measurement of cytokines that have shown predictive potential for suicide in both blood and saliva.
A recent study published in the Biological Psychiatry Journal (https://www.biologicalpsychiatryjournal.com/article/S0006-3223(09)00128-0/fulltext) has shed light on the correlation between specific cytokines in cerebral spinal fluid and suicide. The findings of this study are indeed significant, as they deepen our understanding of the underlying biological mechanisms contributing to suicidal tendencies. However, it's worth noting that obtaining cerebral spinal fluid is a challenging and invasive procedure, limiting its practicality for routine assessment.
The use of blood and saliva for cytokine measurements, as employed in the $TSOI approach, offers a less invasive and more accessible method for monitoring the mental health of anesthesiologists. This approach could potentially help in the early detection of individuals at risk of suicide, providing an opportunity for timely intervention and support.
Incorporating these non-invasive cytokine measurements alongside the inflammation-reducing properties of TSOI and Quadramune, we have the potential to revolutionize the way we address the mental well-being of anesthesiologists and healthcare professionals, ultimately contributing to a healthier and more resilient workforce.
Great work Dr Kesari $TSOI Advisory Panel Doctor!!
$TSOI proudly presents: We applaud our brainy colleagues for revealing the ultimate brain teaser - a map of the mind so detailed, even GPS would be jealous! It's like they've spilled the beans on the brain's secret treasure hunt. 🧠🗺️ Kudos, team! Find out how they're navigating the labyrinth of neurons in the 'Where's Waldo of neuroscience' at the link below:
Read More at https://endpts.com/most-detailed-human-brain-map-yet-is-laying-the-foundation-for-finding-future-cures/ 😄 #BrainyBreakthrough #MindMapMystery"
Well, it seems $TSOI is breaking all the rules in the OTC biotech universe! While other companies are out there playing hard to get with their dividends, $TSOI is like, "Dividends, anyone?" It's like they're the cool parent at the biotech block party, handing out ice cream to all the kids and promising more flavors to come. 🍦🎉
So, if you're an investor in $TSOI, you're not just banking on science; you're also banking on a future of dividends. Who said biotech couldn't be profitable? They've certainly shaken things up in the OTC world! 💸🔬😄
Oh, it's a brilliant conspiracy theory brewing here! Is $TSOI possibly trying to create the illusion of a failed or delayed Phase 3 clinical trial just to make those stock price manipulators sweat in their dark corners? You know, it's like they're playing 4D chess while the manipulators are stuck in a game of checkers. 🤔🕵️♂️
But, seriously, let's not underestimate the power of surprise twists and turns in the stock market drama. Will the thugs take the bait, or will $TSOI be coming out with flying colors? Only time will tell, and it's shaping up to be a plot worthy of a Wall Street thriller! 🍿💼💰
$TSOI When will Campbell Sciences, that intriguing subsidiary of $TSOI, finally uplift and spread its wings into higher territory? Rumor has it that shares might reach the mystical realm of $10 each. 🚀🤑
It's like waiting for a lottery win, only instead of scratching off tickets, you're watching the ticker tape. Will you hit the jackpot and cash in on those high-flying shares? We're all on the edge of our seats, ready to leverage our way to financial glory. Fingers crossed for that magical $10-per-share moment! 🤞💰🎢
Ah, it seems $TSOI is conducting a Phase 3 clinical trial, and they're talking about lung improvement, cytokines, and stem cells. It's like they're throwing a scientific soiree in our lungs, and everyone's invited! 🎉
And the best part? They've confirmed that their hypoxic cultured umbilical-derived mesenchymal stem cells are like the cool party guests who don't cause any trouble - no acute side effects. These stem cells are just here to help, like the bouncers keeping the inflammatory factors under control at the infectious SARS-CoV-2 soirée.
But hold on, folks, this is just the warm-up act. They're setting the stage for larger randomized, double-blinded, multi-center studies, and that's where the real scientific shindig begins. So, grab your lab coats and your party hats – it's time to investigate and celebrate! 🥼🥳🔬
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452932/
In the context of the situation with TSOI and JadiCell Stem Cell Treatment, there are some significant financial and regulatory considerations. TSOI has identified a novel cellular marker associated with the therapeutic response to JadiCell Stem Cell Treatment. However, there have been some puzzling developments:
Exclusive Patent Rights and IND Purchase: Therapeutic Solutions spent $3.1 million on obtaining exclusive patent rights for JadiCell's use in the lung. Additionally, they agreed to purchase the University of Miami's IND (Investigational New Drug) for $4 million. These investments signal their commitment to advancing the treatment.
Phase 3 Trial Delay: Despite the preparations and investments, it appears that Therapeutic Solutions has not moved forward with an FDA-cleared Phase 3 trial, even though such a trial could have substantial financial implications.
Potential Revenues: A successful Phase 3 trial for a biologic treatment in a major organ that addresses an incurable disease can result in substantial revenues. In the case of ARDS (Acute Respiratory Distress Syndrome), the potential financial impact is significant, with a rough estimate indicating possible revenues in the billions.
For example, a calculation based on treating 190,000 ARDS cases at $200,000 per treatment suggests potential revenues of $38 billion annually.
The financial opportunity is substantial, and it's natural to wonder why the project isn't moving forward.
Questions Regarding Proof: There are concerns about the lack of proof or evidence for the "claimed cells" and their therapeutic effectiveness. TSOI has raised questions about this issue, as indicated in their 8K filing.
University of Miami's Involvement: The University of Miami, its employees, including Dr. Ricordi and Dr. Kenyon, and University of Miami Council Javier Peral II, seem to be involved in the situation. However, it is stated that they have not provided answers regarding the proof of the claimed cells.
In summary, the situation raises questions about why a Phase 3 trial, with the potential for substantial revenue, has not moved forward, and there is concern regarding the evidence and proof of the claimed cells.
I think the California facility may help PHBI bring in some revenues and also possiblity of revenue from live rosin or micro business license
$PHBI yeah..rolled my dice at these levels..hoping fo a penny. before end of the year
Oh, absolutely! Because who doesn't love a good old-fashioned infomercial, right? "But wait, there's more!" If you act now, you might even get a free set of steak knives with your $TSOI stock analysis!
I mean, who needs boring old links to back up claims when you can have the suspense of wondering whether they're going to reveal the secret ingredient for their stock success?
So, don't worry about that missing link, my friend. Just sit back, relax, and enjoy the show as $TSOI keeps us all entertained with its JADICELLS SCIENCE. Who knows, maybe they'll even throw in a catchy PATENT next time! 🎶 "Invest in TSOI, and watch your dreams take flight!" 🚀
Well, you know, $TSOI is really setting the bar high in the world of medical mystery and intrigue! Who needs those boring phase 2 or 3 trials anyway? Rumors and whispers in dark alleyways are clearly the way to go when you want to keep everyone guessing.
As for that claim about saving 100 patients with JADICELLS, I have to wonder if they're using a secret code that only they understand. It's like a medical thriller plot unfolding right before our eyes!
As for disinformation, well, who needs the truth when you can have a good laugh trying to decipher their press releases?
$TSOI, you're like the Houdini of the biotech world – always disappearing into the mist of uncertainty, leaving us all scratching our heads and wondering, "What's next?" Keep the next PATENT coming!
$TSOI has consistently demonstrated its commitment to advancing medical science and improving patient outcomes. While several biotech companies like $MESO, $BCLI, $GNPX, and $ATHX have faced challenges in treating diseases such as lung degeneration, ARDS, and breast cancer using umbilical cord mesenchymal stem cells, it raises important questions about the potential efficacy of JADICELLS in achieving success in disease treatment and ultimately saving lives.
It's worth noting that $TSOI has a proven track record, having successfully saved the lives of over 100 patients with JADICELLS. This remarkable achievement underscores the promise of their innovative approach and highlights the potential for JADICELLS to make a significant impact in the field of regenerative medicine.
As the medical community continues to explore and refine the applications of stem cell therapies, $TSOI's dedication to pioneering treatments like JADICELLS remains a beacon of hope for patients seeking effective solutions to challenging medical conditions. Their ongoing efforts and successes emphasize the importance of rigorous research and development in the quest for groundbreaking medical breakthroughs.
$12,315 now at .0013
I am here to say that I still hold my investment of over 180K in $TSOI and stand by my investment choice
what does that mean! i dont know
I just voice my opinion as long time shareholder trust that at some point I shall I get my investment back in $TSOI
As I mentioned I am LONG shareholder after reading through the whole SEC filings I had come to conclusion that DR Patel and Dr Ricordi has violated the license agreeement between TSOI an JADICELL LLC
$TSOI how would I know that? other than the fact I am since shareholder since 2019.